Screening of Antiviral Components of Yinhuapinggan Granule and Protective Effects of Yinhuapinggan Granule on MDCK Cells with Influenza A/H1N1 Virus

Figure 4

Effects of YHPG and the main active components on CPE of MDCK cells infected by influenza A/H1N1 virus (×10) after 24 h of treatment: (a) control group; (b) control+YHPG group (625 μg·mL^-1); (c) mock group; (d) ribavirin group (780 μg·mL^-1); (e) high-dose YHPG group (625 μg·mL^-1); (f) medium-dose YHPG group (312.5 μg·mL^-1); (g) low-dose YHPG group (156 μg·mL^-1); (h) ephedrine hydrochloride group (62.5 μg·mL^-1); (i) pseudoephedrine hydrochloride group (62.5 μg·mL^-1); (j) chlorogenic acid group (31.25 μg·mL^-1); (k) luteoloside group (250 μg·mL^-1); (l) emodin group (62.5 μg·mL^-1).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)